Researchers Report ScreenCell® Usage For Colorectal Cancer - CTC Biomarker

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARIS--(BUSINESS WIRE)--In a recent paper, Cancer Biomarkers (Cancer Biomarkers 14 (2014) p.145–150), researchers at Rouen University Hospital, Rome University Hospital-La Sapienza, and University of Medicine and Pharmacy, Cluj-Napoca, Romania report on the use of the ScreenCell Cyto device to capture and characterize Circulating Tumor Cells (CTCs) from patients with colorectal cancer (CRC). This is the first preliminary report on the use of ScreenCell with samples from CRC patients.

The authors describe the issue with using antibody capture methods for separation of CTCs: “CTCs undergo EMT (epithelial-mesenchymal transition); thus, it is important to choose the right antibody for their characterization. This finding could also explain why microfiltrating approaches seem to be more efficient than technologies based on immunomagnetic or microfluidic separation, which rely on the presence of EpCam antigen at the surface of the CTC.”

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC